Chen X, Arshad A, Qing H, et al. Enzymatic condensation of dopamine and acetaldehyde: A salsolinol synthase from rat brain [J]. Biologia, 2011, 66(6): 1183-1188.
[2]
Labandeira-Garcia J L, Rodriguez-Perez A I, Villar-Cheda B, et al. Rho kinase and dopaminergic degeneration: A promising therapeutic targetforparkinson'sdisease[J].Neuroscientist,2014, 1073858414554954.
[3]
Litvan I, Bhatia K P, Burn D J, et al. Movement disorders society scientific issues committee report: Sic task force appraisal of clinical diagnostic criteria for parkinsonian disorders[J]. Movement Disorder, 2003, 18(5): 467-486.
[4]
Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models[J]. Neuron, 2003, 39(6): 889-909.
[5]
Langston J W, Ballard P, Tetrud J W, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis[J]. Science, 1983, 219(4587): 979-980.
[6]
Nicklas W J, Vyas I, Heikkila R E. Inhibition of nadh-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine[J]. Life Science, 1985, 36(26): 2503-2508.
[7]
Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of parkinson disease[J]. Journal of Clinical Investigation, 2009, 119(1): 182-192.
[8]
Calopa M, Bas J, Callen A, et al. Apoptosis of peripheral blood lymphocytes in parkinson patients[J]. Neurobiology of Disease, 2010, 38 (1): 1-7.
[9]
Saunders R N, Metcalfe M S, Nicholson M L. Rapamycin in transplantation: A review of the evidence[J]. Kidney International, 2001, 59(1): 3-16.
[10]
Pettit D A, Williamson J, Cabral G A, et al. In vitro destruction of nerve cell cultures by acanthamoeba spp: A transmission and scanning electron microscopy study[J]. Journal of Parasitol, 1996, 82(5): 769- 777.
[11]
Funk N, Wieghofer P, Grimm S, et al. Characterization of peripheral hematopoietic stem cells and monocytes in parkinson's disease[J]. Movement Disorder, 2013, 28(3): 392-395.
[12]
Deleidi M, Gasser T. The role of inflammation in sporadic and familial parkinson's disease[J]. Cellular and Molecular Life Sciences, 2013, 70 (22): 4259-4273.
[13]
Naoi M, Maruyama W, Nagy G M. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: Occurrence, metabolism and function in human brains[J]. Neurotoxicology, 2004, 25 (1-2): 193-204.
[14]
Mravec B. Salsolinol, a derivate of dopamine, is a possible modulator of catecholaminergic transmission: A review of recent developments[J]. Physiological Research, 2006, 55(4): 353-364.
[15]
Deng Y, Luan Y, Qing H, et al. The formation of catechol isoquinolines in pc12 cells exposed to manganese[J]. Neuroscience Letters, 2008, 444(2): 122-126.
[16]
Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/ life regulator in apoptosis and necrosis[J]. Annual Review of Physiology, 1998, 60: 619-642.
[17]
Maruyama W, Dostert P, Naoi M. Dopamine-derived 1-methyl-6,7- dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: In vivo and in vitro studies[J]. Journal of Neurochemstry, 1995, 64(6): 2635-2643.
[18]
Alnemri E S, Livingston D J, Nicholson D W, et al. Human ice/ced-3 protease nomenclature[J]. Cell, 1996, 87(2): 171.
